Generated by AI
Insulet Corporation is a medical device company focused on insulin delivery and diabetes management. Its flagship Omnipod platform includes wearable, tubeless insulin management systems designed to deliver continuous insulin without traditional pump tubing or multiple daily injections. The product line includes Omnipod 5, Omnipod DASH, and the Classic Omnipod, along with related pods, controllers, and diabetes management software that support day-to-day glucose control. Insulet also works with selected partners to adapt its Pod technology for the subcutaneous delivery of non-insulin therapies in other medical areas. Headquartered in Acton, Massachusetts, Insulet serves patients and healthcare providers across multiple international markets through direct sales and distribution channels.
Website100 Nagog Park
Acton, MA, 01720
United States
The latest articles about PODD.
Tandem Diabetes Care (TNDM) stock gains and Insulet (PODD) slips as Stifel changes their ratings, citing the market trends for tubeless insulin pumps. Read more here.
Summary of Sep 24's posts. Generated by AI.
Summary of Feb 18's posts. Generated by AI.
Insulet is undervalued, trading at a sub-median multiple despite 20% revenue growth and expanding margins. Learn more about PODD stock here.
Summary of May 8's posts. Generated by AI.
Summary of Sep 24's posts. Generated by AI.
Investors talking about PODD also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.